Literature DB >> 27271990

High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.

Adrian Box1, Mohammed Alshalalfa2, Samar A Hegazy1,2, Bryan Donnelly2,3, Tarek A Bismar4,5,6,7,8.   

Abstract

Alpha-methylacyl-CoA racemase (AMACR) is a well-characterized marker extensively utilized in prostate cancer (PCA) diagnosis. However, the prognostic value of AMACR expression and its relation to TMPRSS2-ERG gene rearrangement as one of the most common molecular alterations in PCA is not fully explored. AMACR expression was investigated in a cohort of 218 men with localized PCA treated by radical prostatectomy and correlated with ERG and various clinical and pathological parameters. In vitro studies assessed AMACR changes to ERG knockdown and other related genes. In addition, bioinformatics validated the significance of AMACR/ERG expression and assessed relevant genetic signatures in relation to AMACR/ERG expression. AMACR expression was significantly associated with disease progression and with ERG (p ∼0). Seventeen percent of cancer foci showed negative/weak AMACR expression while being ERG positive. High AMACR expression was significantly associated with positive surgical margins (p = 0.01), specifically in tumors with lower Gleason score <7, with ∼95 % exhibiting positive surgical margin (p = 0.008). High AMACR showed marginal association with PSA biochemical recurrence (BCR) (p = 0.06) which was slightly more pronounced in ERG-positive tumors (p = 0.04). This was validated in other public cohorts. However, in this cohort, the association with BCR was not statistically significant in multivariate analysis (p = 0.09). Using in vitro cellular models, AMACR messenger RNA (mRNA) expression, but not protein levels, showed an association with ERG expression. We report for the first time a significant association between AMACR and ERG with prognostic implication. Patients with high AMACR/ERG-positive PCA may be at higher risk for disease progression, and additional studies in larger cohorts are needed to confirm the above findings. Functional studies investigating the molecular pathways connecting AMACR and ERG may provide an additional insight into PCA progression pathways.

Entities:  

Keywords:  AMACR; Biochemical recurrence; Biomarkers; Disease progression; ERG; PSA relapse; Prognosis; Surgical margin

Mesh:

Substances:

Year:  2016        PMID: 27271990     DOI: 10.1007/s13277-016-5075-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  56 in total

1.  Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.

Authors:  Jonathan I Epstein; Lars Egevad; Peter A Humphrey; Rodolfo Montironi
Journal:  Am J Surg Pathol       Date:  2014-08       Impact factor: 6.394

2.  ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.

Authors:  Sarah Minner; Malaika Enodien; Hüseyin Sirma; Andreas M Luebke; Antje Krohn; Pascale S Mayer; Ronald Simon; Pierre Tennstedt; Julia Müller; Laura Scholz; Jan C Brase; Alvin Y Liu; Hartmut Schlüter; Klaus Pantel; Udo Schumacher; Carsten Bokemeyer; Thomas Steuber; Markus Graefen; Guido Sauter; Thorsten Schlomm
Journal:  Clin Cancer Res       Date:  2011-07-26       Impact factor: 12.531

3.  Purification and characterization of an alpha-methylacyl-CoA racemase from human liver.

Authors:  W Schmitz; C Albers; R Fingerhut; E Conzelmann
Journal:  Eur J Biochem       Date:  1995-08-01

4.  Branched fatty acids in dairy and beef products markedly enhance alpha-methylacyl-CoA racemase expression in prostate cancer cells in vitro.

Authors:  James A Mobley; Irwin Leav; Patrick Zielie; Chad Wotkowitz; James Evans; Ying-Wai Lam; Byung Suk L'Esperance; Zhong Jiang; Shuk-Mei Ho
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-08       Impact factor: 4.254

Review 5.  Alpha-methylacyl-CoA racemase--an 'obscure' metabolic enzyme takes centre stage.

Authors:  Matthew D Lloyd; Daniel J Darley; Anthony S Wierzbicki; Michael D Threadgill
Journal:  FEBS J       Date:  2008-02-12       Impact factor: 5.542

6.  Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer.

Authors:  Shan Zha; Sacha Ferdinandusse; Simone Denis; Ronald J Wanders; Charles M Ewing; Jun Luo; Angelo M De Marzo; William B Isaacs
Journal:  Cancer Res       Date:  2003-11-01       Impact factor: 12.701

7.  Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues.

Authors:  Jiangling J Tu; Stephen Rohan; Jean Kao; Naoki Kitabayashi; Susan Mathew; Yao-Tseng Chen
Journal:  Mod Pathol       Date:  2007-07-13       Impact factor: 7.842

8.  TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort.

Authors:  Andrew D Darnel; Christopher J Lafargue; Robin T Vollmer; Jacques Corcos; Tarek A Bismar
Journal:  Cancer Biol Ther       Date:  2009-02-04       Impact factor: 4.742

9.  ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification.

Authors:  B Furusato; S-H Tan; D Young; A Dobi; C Sun; A A Mohamed; R Thangapazham; Y Chen; G McMaster; T Sreenath; G Petrovics; D G McLeod; S Srivastava; I A Sesterhenn
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-06-29       Impact factor: 5.554

10.  Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.

Authors:  A H M Reid; G Attard; L Ambroisine; G Fisher; G Kovacs; D Brewer; J Clark; P Flohr; S Edwards; D M Berney; C S Foster; A Fletcher; W L Gerald; H Møller; V E Reuter; P T Scardino; J Cuzick; J S de Bono; C S Cooper
Journal:  Br J Cancer       Date:  2010-01-26       Impact factor: 7.640

View more
  6 in total

1.  Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort.

Authors:  Jennifer Cullen; Denise Young; Yongmei Chen; Michael Degon; James Farrell; Jason Sedarsky; Wagner Baptiste; Philip Rosen; Vladimir Tolstikov; Michael Kiebish; Jacob Kagan; Sudhir Srivastava; Huai-Ching Kuo; Joel T Moncur; Inger L Rosner; Niven Narain; Viatcheslav Akmaev; Gyorgy Petrovics; Albert Dobi; David G McLeod; Shiv Srivastava; Isabell A Sesterhenn
Journal:  Eur Urol Focus       Date:  2017-03-11

2.  Correlation of NTRK1 Downregulation with Low Levels of Tumor-Infiltrating Immune Cells and Poor Prognosis of Prostate Cancer Revealed by Gene Network Analysis.

Authors:  Arash Bagherabadi; Amirreza Hooshmand; Nooshin Shekari; Prithvi Singh; Samaneh Zolghadri; Agata Stanek; Ravins Dohare
Journal:  Genes (Basel)       Date:  2022-05-08       Impact factor: 4.141

Review 3.  Autophagy and organelle homeostasis in cancer.

Authors:  Dannah R Miller; Andrew Thorburn
Journal:  Dev Cell       Date:  2021-03-08       Impact factor: 12.270

Review 4.  Emerging proteomics biomarkers and prostate cancer burden in Africa.

Authors:  Henry A Adeola; Jonathan M Blackburn; Timothy R Rebbeck; Luiz F Zerbini
Journal:  Oncotarget       Date:  2017-06-06

Review 5.  Metabolomics Contributions to the Discovery of Prostate Cancer Biomarkers.

Authors:  Nuria Gómez-Cebrián; Ayelén Rojas-Benedicto; Arturo Albors-Vaquer; José Antonio López-Guerrero; Antonio Pineda-Lucena; Leonor Puchades-Carrasco
Journal:  Metabolites       Date:  2019-03-08

Review 6.  Peroxisome Metabolism in Cancer.

Authors:  Jung-Ae Kim
Journal:  Cells       Date:  2020-07-14       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.